Mavenir Proves AMD Technology across its Open RAN OpenBeam™ Radio and Converged Packet Core Portfolio
1.2.2023 17:00:00 EET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud, today announced new initiatives in collaboration with AMD to help Communication Service Providers (CSPs) in their transition to cloud-native telecommunication networks.
First, Mavenir and AMD have been collaborating in Open RAN to build industry leading radio technology. Mavenir has incorporated the AMD Zynq™ Ultrascale+™ RFSoC devices into Mavenir’s OpenBeam™ Radio Portfolio and, through this partnership, both companies continue to work together to introduce new functionality, features, and capabilities to customers.
Secondly, Mavenir’s Converged Packet Core has been validated on AMD EPYC™ CPUs – This means Mavenir’s cloud-native, fully containerized, virtualized Converged Packet Core (4G & 5G) solution can now be deployed on AMD EPYC server CPUs to provide CSPs with more options to implement virtual network functions in cloud data centers.
The elements validated include AMF, SMF, UPF, UDSF, NRF, NSSF, AUSF, UDM, and UDR network functions. Additionally, PCF, NEF, BSF, MME, SecGw, PCRF, MME and SGSN network functions will be validated in the coming months.
“Mavenir’s commitment to enabling networks built on software that runs on any cloud revolves around giving CSPs the ability to use the best components that fit their specific needs, in the cell-site and in the data center,” said Bejoy Pankajakshan, EVP, Chief Technology and Strategy Officer, Mavenir. “Mavenir and AMD are working together to give CSPs multiple options and help them optimize power consumption, network efficiency and total cost of ownership in the radio access as well as the core network.”
“Cloud-native telecom networks empower CSPs with systems that offer flexibility, lower operational cost, ease of system management, and a broader ecosystem for value add, innovation, and upgrade capabilities as network requirements grow,” said Salil Raje, senior vice president and general manager, Data Center and Communications Group, AMD. “We are extremely proud of our close collaboration with Mavenir to help deliver exceptional TCO and predictable scalability along with high performance and power efficient solutions to telecommunications operators leveraging AMD data center products.”
Mavenir’s OpenBeam innovative radio portfolio is specifically designed for the growing needs of CSPs with agile, cost-efficient, intelligent radios to meet critical demands on the network now, and as the network changes and expands. The radio solutions can be used for a wide range of use cases, including basic coverage across all frequency bands, outdoor small cells, for public and private networks providing business and consumer services in both urban and rural environments.
Mavenir’s Converged Packet Core is an end-to-end, fully containerized portfolio that offers multi-generational support to modernize existing mobile networks while providing a cost-effective journey to 5G. Its cloud-native architecture, with applications and services purpose-built for the cloud model, offers easy scaling, hardware decoupling, agility, portability and resiliency across public, private and hybrid clouds. Its web-scale granular microservice architecture meets carrier-grade requirements such as high availability, security, and performance.
To know more about the joint collaboration, visit Mavenir (hall 2 stand 2H60) and AMD (hall 2 stand 2M61) at Mobile World Congress 2023 in Barcelona (February 27th – March 2nd).
AMD, the AMD Arrow logo, EPYC™, Zynq™ and Ultrascale+™, and combinations thereof, are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005147/en/
Contact information
PR Contact:
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
